{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:28:43Z","timestamp":1793953723255,"version":"4.8.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"publisher","award":["RIA2019S-2652"],"award-info":[{"award-number":["RIA2019S-2652"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000866","name":"International AIDS Vaccine Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010067","name":"Government of Arag\u00f3n","doi-asserted-by":"publisher","award":["B35_23R"],"award-info":[{"award-number":["B35_23R"]}],"id":[{"id":"10.13039\/501100010067","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijid.2026.108513","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T15:02:05Z","timestamp":1772377325000},"page":"108513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Toward tuberculosis elimination: An update on tuberculosis vaccines in clinical trials"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-5478","authenticated-orcid":false,"given":"Carlos","family":"Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Gonzalo-Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacho","family":"Aguil\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Arbu\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108513_bib0001","series-title":"Global Tuberculosis Report 2025","year":"2025"},{"key":"10.1016\/j.ijid.2026.108513_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ijid.2026.108513_bib0003","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108513_bib0004","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrmicro2668","article-title":"The development of vaccines: how the past led to the future","volume":"9","author":"Plotkin","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijid.2026.108513_bib0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature10124","article-title":"A 2020 vision for vaccines against HIV, tuberculosis and malaria","volume":"473","author":"Rappuoli","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2026.108513_bib0006","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijid.2026.108513_bib0007","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108513_bib0008","article-title":"Effectiveness of the primary Bacillus Calmette-Gu\u00e9rin vaccine against the risk of mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data","author":"Pelzer","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijid.2026.108513_bib0009","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","article-title":"Comparative genomics of BCG vaccines by whole-genome DNA microarray","volume":"284","author":"Behr","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ijid.2026.108513_bib0010","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1073\/pnas.0700869104","article-title":"Genome plasticity of BCG and impact on vaccine efficacy","volume":"104","author":"Brosch","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijid.2026.108513_bib0011","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(21)00403-5","article-title":"100 years of mycobacterium bovis bacille Calmette-Gu\u00e9rin","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108513_bib0012","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/infdis\/jir240","article-title":"Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?","volume":"204","author":"Aaby","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108513_bib0013","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.it.2013.04.004","article-title":"A small jab \u2013 a big effect: nonspecific immunomodulation by vaccines","volume":"34","author":"Benn","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ijid.2026.108513_bib0014","first-page":"89","article-title":"Defining trained immunity and its role in health and disease","volume":"173","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijid.2026.108513_bib0015","series-title":"Global Tuberculosis Report 2023","year":"2023"},{"key":"10.1016\/j.ijid.2026.108513_bib0016","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.05.00109904","article-title":"The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?","volume":"26","author":"Martin","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2026.108513_bib0017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tube.2013.11.003","article-title":"A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data","volume":"94","author":"Mcshane","year":"2014","journal-title":"Tuberculosis (Edinburgh, Scotland)"},{"key":"10.1016\/j.ijid.2026.108513_bib0018","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.tube.2016.05.012","article-title":"Novel approaches to preclinical research and TB vaccine development","volume":"99","author":"Walker","year":"2016","journal-title":"Tuberculosis (Edinburgh, Scotland)"},{"key":"10.1016\/j.ijid.2026.108513_bib0019","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2006.02.013","article-title":"The development and impact of tuberculosis vaccines","volume":"124","author":"Young","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2026.108513_bib0020","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/79631","article-title":"Is the development of a new tuberculosis vaccine possible?","volume":"6","author":"Kaufmann","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2026.108513_bib0021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tube.2004.09.009","article-title":"Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis","volume":"85","author":"Williams","year":"2005","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijid.2026.108513_bib0022","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3389\/fimmu.2017.01203","article-title":"TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development","volume":"8","author":"Kaufmann","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2026.108513_bib0023","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.tube.2016.05.013","article-title":"TB vaccines in clinical development","volume":"99","author":"Ginsberg","year":"2016","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijid.2026.108513_bib0024","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1016\/j.celrep.2017.02.057","article-title":"Recombinant BCG expressing ESX-1 of mycobacterium marinum combines low virulence with cytosolic immune signaling and improved TB protection","volume":"18","author":"Gr\u00f6schel","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijid.2026.108513_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1246826","article-title":"Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates","volume":"14","author":"White","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2026.108513_bib0026","first-page":"1","article-title":"A BCG kill switch strain protects against mycobacterium tuberculosis in mice and non-human primates with improved safety and immunogenicity","author":"Smith","year":"2025","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijid.2026.108513_bib0027","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.chom.2020.10.003","article-title":"Ultra-low dose aerosol infection of mice with mycobacterium tuberculosis more closely models Human tuberculosis","volume":"29","author":"Plumlee","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijid.2026.108513_bib0028","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167762","article-title":"Host genetic background is a barrier to broadly effective vaccine-mediated protection against tuberculosis","volume":"133","author":"Lai","year":"2023","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ijid.2026.108513_bib0029","first-page":"1","article-title":"Review the status of tuberculosis vaccine development","author":"Schrager","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108513_bib0030","article-title":"Update on TB vaccine pipeline","volume":"10","author":"Martin","year":"2020","journal-title":"Appl Sci (Switzerland)"},{"key":"10.1016\/j.ijid.2026.108513_bib0031","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2026.108513_bib0032","doi-asserted-by":"crossref","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","article-title":"MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques","volume":"4","author":"Verreck","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2026.108513_bib0033","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.tube.2013.01.003","article-title":"Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG","volume":"93","author":"Tameris","year":"2013","journal-title":"Tuberculosis (Edinburgh, Scotland)"},{"key":"10.1016\/j.ijid.2026.108513_bib0034","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"379","author":"Meeren","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108513_bib0035","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108513_bib0036","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1016\/j.vaccine.2005.03.001","article-title":"New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development","volume":"23","author":"Kamath","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2026.108513_bib0037","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.vaccine.2009.12.083","article-title":"The second Geneva Consensus: recommendations for novel live TB vaccines","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2026.108513_bib0038","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12879-023-08092-4","article-title":"Safety and efficacy of tuberculosis vaccine candidates in low- and middle-income countries: a systematic review of randomised controlled clinical trials","volume":"23","author":"Wilson","year":"2023","journal-title":"Bmc Infect Dis"},{"key":"10.1016\/j.ijid.2026.108513_bib0039","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41541-023-00666-2","article-title":"A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG","volume":"8","author":"Dijkman","year":"2023","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.ijid.2026.108513_bib0040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40121-023-00806-0","article-title":"Safety and immunogenicity of the ID93 + GLA-SE tuberculosis vaccine in BCG-vaccinated healthy adults: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"12","author":"Choi","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2026.108513_bib0041","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jmii.2014.03.005","article-title":"Recombinant tuberculosis vaccine AEC\/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection","volume":"48","author":"Lu","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijid.2026.108513_bib0042","first-page":"652","article-title":"Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study","volume":"8","author":"Tkachuk","year":"2020","journal-title":"Nato Adv Sci Inst Se"},{"key":"10.1016\/j.ijid.2026.108513_bib0043","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-0189-2","article-title":"Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques","volume":"5","author":"Vierboom","year":"2020","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.ijid.2026.108513_bib0044","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00100-19","article-title":"Tuberculosis vaccine development: progress in clinical evaluation","volume":"33","author":"Sable","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijid.2026.108513_bib0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155655","article-title":"Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans","volume":"7","author":"Jeyanathan","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijid.2026.108513_bib0046","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/vaccines9040394","article-title":"Mucosal influenza vector vaccine carrying TB10.4 and HspX antigens provides protection against mycobacterium tuberculosis in mice and Guinea pigs","volume":"9","author":"Sergeeva","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ijid.2026.108513_bib0047","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1016\/j.vaccine.2020.09.055","article-title":"DAR-901 vaccine for the prevention of infection with mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: a randomized controlled, double-blind phase 2b trial","volume":"38","author":"Munseri","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2026.108513_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089612","article-title":"Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection","volume":"9","author":"Nell","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2026.108513_bib0049","volume":"14","author":"Singh","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijid.2026.108513_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00222-5","article-title":"Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial","author":"Cotton","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108513_bib0051","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2026.108513_bib0052","doi-asserted-by":"crossref","first-page":"e1030","DOI":"10.1016\/S2214-109X(25)00046-4","article-title":"Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b\u20132a, double-blind, dose-escalation, randomised controlled trial","volume":"13","author":"Luabeya","year":"2025","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.ijid.2026.108513_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105628","article-title":"Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting","volume":"114","author":"Tameris","year":"2025","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ijid.2026.108513_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.06.049","article-title":"MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG","author":"Mart\u00edn","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2026.108513_bib0055","article-title":"Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis","volume":"16","author":"Voss","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2026.108513_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1427371","article-title":"A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adults","volume":"15","author":"Fredsgaard-Jones","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2026.108513_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101211","article-title":"Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis","volume":"6","author":"Gbesemete","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijid.2026.108513_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101278","article-title":"Controlled human infection with mycobacterium tuberculosis: practical considerations for clinical trials","author":"Seshadri","year":"2026","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijid.2026.108513_bib0059","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1038\/s41467-025-60285-4","article-title":"Early mucosal responses following a randomised controlled human inhaled infection with attenuated mycobacterium bovis BCG","volume":"16","author":"Marshall","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2026.108513_bib0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108513_bib0061","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa2412381","article-title":"BCG revaccination for the prevention of mycobacterium tuberculosis infection","volume":"392","author":"Schmidt","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108513_bib0062","author":"Borges","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108513_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00127-7","article-title":"Implications of subclinical tuberculosis for vaccine trial design and global effect","author":"Churchyard","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijid.2026.108513_bib0064","doi-asserted-by":"crossref","first-page":"k2738","DOI":"10.1136\/bmj.k2738","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"Behr","year":"2018","journal-title":"BMJ (Clinical Research Ed)"},{"key":"10.1016\/j.ijid.2026.108513_bib0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1164\/rccm.202011-4239PP","article-title":"Latent tuberculosis: two centuries of confusion","volume":"204","author":"Behr","year":"2021","journal-title":"Am J Resp Crit Care"},{"key":"10.1016\/j.ijid.2026.108513_bib0066","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41564-024-01683-0","article-title":"Rethinking the burden of latent tuberculosis to reprioritize research","volume":"9","author":"Behr","year":"2024","journal-title":"Nat Microbiol"},{"issue":"12","key":"10.1016\/j.ijid.2026.108513_bib0067","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1164\/rccm.202007-2686OC","article-title":"Antigen-specific T cell activation distinguishes between recent and remote tuberculosis infection","volume":"203","author":"Mpande","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2026.108513_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127301","article-title":"Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants","volume":"61","author":"Cobelens","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2026.108513_bib0069","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1016\/S1473-3099(25)00305-6","article-title":"The participation of people deprived of liberty in tuberculosis vaccine trials: should they be protected from research, or through research?","volume":"25","author":"Andrews","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108513_bib0070","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/496930","article-title":"The Spanish royal philanthropic expedition to bring smallpox vaccination to the New World and Asia in the 19th century","volume":"41","author":"Franco-Paredes","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226001487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226001487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:09:17Z","timestamp":1793952557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226001487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":70,"alternative-id":["S1201971226001487"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108513","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward tuberculosis elimination: An update on tuberculosis vaccines in clinical trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108513"}}